12:00 AM
Aug 08, 2016
 |  BC Extra  |  Company News

Celgene declines Acetylon option

Celgene Corp. (NASDAQ:CELG) revealed in a regulatory filing that it did not exercise its option to acquire Acetylon Pharmaceuticals Inc. (Boston, Mass.). Celgene allowed the option to expire in May. It paid $100 million up...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >